Tango Therapeutics Inc’s recent filing unveils that its 10% Owner Third Rock Ventures IV, L.P. unloaded Company’s shares for reported $4.01 million on Sep 25 ’25. In the deal valued at $8.02 per share,500,000 shares were sold. As a result of this transaction, Third Rock Ventures IV, L.P. now holds 13,863,975 shares worth roughly $120.62 million.
Then, Third Rock Ventures IV, L.P. bought 500,000 shares, generating $3,900,000 in total proceeds.
Before that, Third Rock Ventures IV, L.P. sold 363,541 shares. Tango Therapeutics Inc shares valued at $2,559,329 were divested by the 10% Owner at a price of $7.04 per share. As a result of the transaction, Third Rock Ventures IV, L.P. now holds 14,363,975 shares, worth roughly $124.97 million.
Piper Sandler initiated its Tango Therapeutics Inc [TNGX] rating to an Overweight in a research note published on August 19, 2025; the price target was $11. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering TNGX with “an Overweight” recommendation on April 04, 2024. Piper Sandler started covering the stock on February 12, 2024. It rated TNGX as “an Overweight”.
Price Performance Review of TNGX
On Tuesday, Tango Therapeutics Inc [NASDAQ:TNGX] saw its stock jump 2.72% to $8.7. Over the last five days, the stock has gained 19.34%. Tango Therapeutics Inc shares have risen nearly 32.82% since the year began. Nevertheless, the stocks have risen 181.55% over the past one year.
How much short interest is there in Tango Therapeutics Inc?
A steep rise in short interest was recorded in Tango Therapeutics Inc stocks on 2025-09-30, growing by 8.41 million shares to a total of 33.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 25.4 million shares. There was a rise of 24.88%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 08, 2023 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
